EFFICACY OF ONCE-WEEKLY ADMINISTRATION OF CTP-MODIFIED HUMAN GROWTH HORMONE (MOD-4023): 24-MONTH COMPLETE DATABASE RESULTS OF A PHASE 2 STUDY IN CHILDREN WITH GROWTH HORMONE DEFICIENCY

Abstract:

OPKO Biologics is developing bio-better long-acting versions of existing therapeutic proteins utilizing a technology called CTP.

Тип: Article